Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.40 |
| ▸ | TK1 | P04183 | 3/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 6/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749203 | 1.00 | KIF11 (0.53) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL5899878 | 1.00 | KIF11 (0.53) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL5967855 | 0.89 | SLC6A11 (0.49) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL5604595 | 0.89 | SLC6A11 (0.49) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL5604514 | 0.89 | SLC6A11 (0.49) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL8972396 | 0.86 | KIF11 (0.47) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL27997026 | 0.85 | KIF11 (0.57) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL6839990 | 0.84 | MEN1 (0.50) | CYP2C19LMNA | |
| SCHEMBL14923123 | 0.81 | KIF11 (0.53) | KIF11CYP2C19CYP2C9ALOX15TSHR | |
| SCHEMBL20341349 | 0.81 | LMNA (0.52) | KIF11CYP2C19CYP2C9ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
| CN-111471056-B | Macrocyclic immunomodulator | 成都先导药物开发股份有限公司 | 2021-07-02 | — | — | CN | disclosed |
| CN-111471056-A | Macrocyclic immunomodulator | 成都先导药物开发股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| EP-1966217-B1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-05-08 | — | — | EP | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966217-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-6989399-B2 | Antiamyloid phenylsulfonamides: N-alkanol derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-24 | — | — | US | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-20040097572-A1 | Antiamyloid phenylsulfonamides: N-alkanol derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | KIF11 1526/4885CYP2C19 4041/4885CYP2C9 4265/4885 |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | KIF11 4743/4885CYP2C19 117/4885CYP2C9 196/4885 |
| US-20040097572-A1 | Antiamyloid phenylsulfonamides: N-alkanol derivatives | APP, PSEN1, PSEN2 | KIF11 4680/4885CYP2C19 4569/4885CYP2C9 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.